-
Cancer Research UK, CPF and NCI partner to develop tests to analyse RAS inhibitors
pharmaceutical-technology
April 20, 2017
Cancer Research UK and the Cancer Research Technology Pioneer Fund (CPF) National Cancer Institute (NCI), US, have ...
-
Roche's drug scores expanded FDA indication in advanced bladder cancer
pharmafile
April 19, 2017
Roche’s Genentech has revealed that its immunotherapy drug Tecentriq (atezolizumab) is now enjoying an expanded ...
-
CR UK, CRT Pioneer Fund and the NCI link on RAS
pharmatimes
April 19, 2017
Cancer Research UK and the Cancer Research Technology Pioneer Fund (CPF) are committing ￡2.5 million in collaboration...
-
BMS links with Apexigen to test cancer immunotherapy combo
pharmatimes
April 14, 2017
Bristol-Myers Squibb and Apexigen are to test a combination of Opdivo and the latter’s investigational compound APX005M in patients with advanced solid tumours.
-
NICE’s draft guidance ignores recommendation of Opdivo to treat cancer, Bristol-Myers Squibb says
pharmaceutical-technology
April 14, 2017
US-based Bristol-Myers Squibb has confirmed that the National Institute for Health and Care Excellence (NICE) has issued draft guidance that ignores recommendation of investigational cancer immunotherapy Opdivo (nivolumab).
-
Cancer can be diagnosed by Google's artificial intelligence
biospectrumasia
April 14, 2017
The system is able to scan samples to determine whether or not tissues are cancerous
-
SMC u-turn backs Roche’s Kadcyla for breast cancer
pharmatimes
April 12, 2017
Women in Scotland will be among the first in the UK to have routine NHS access to Roche’s breast cancer drug Kadcyla ...
-
NICE turns down BMS' Opdivo for head and neck cancer
pharmafile
April 11, 2017
Bad news for Bristol-Myers Squibb as NICE chooses not to recommend its immunotherapy drug Opdivo (nivolumab) for use in head and neck cancer treatment.
-
Immune-Onc and UT System to develop new biotherapeutics for cancer immunotherapy
pharmaceutical-technology
April 11, 2017
Immune-Onc Therapeutics has entered an agreement with two member institutions of the University of Texas System (UT ...
-
Antibiotics overuse could boost bowel cancer risk
pharmatimes
April 07, 2017
Long-term use of antibiotics can significantly raise the risk of developing polyps on the bowel that can lead to cancer...
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight July 2025
